Published 1 hour ago • loading... • Updated 57 minutes ago
Target posts best sales growth in five years, raises guidance
The retailer said revitalized merchandise, same-day delivery and price cuts drove a third straight quarter of comparable sales gains.
Lifeloc reported Q3 2026 financial results on Monday, detailing net revenue and a net loss for the period ending September 30, 2026.
Since December 31, 2025, Lifeloc has reduced its headcount to stabilize cash flow, while prioritizing core alcohol-testing products to fund the ongoing development of its drug analyzer.
Validated against liquid chromatography-mass spectrometry, the SpinDetect platform established the scientific foundation necessary for the device's upcoming regulatory clearances and commercial use.
Shifting from the previously anticipated timeline, the company delayed the limited commercial launch of the SpinDetect analyzer to focus on generating incremental revenue from core product lines.
Incremental revenue from core products will support fabrication and regulatory preparation as Lifeloc aims to "stabilize cash flow" for its ongoing development projects, management said.